ClinicalTrials.gg
CompletedNCT03262233Updated Apr 23, 2019Results posted

Stress Neuroadaptation in Tobacco Dependence

A Phase 4 interventional study of nicotine and placebo in Nicotine Dependence, sponsored by University of Wisconsin, Madison. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-04-23.

Sponsored by University of Wisconsin, Madison · Phase 4, Interventional, and Health services research

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Apr 2015, registered Aug 2017).
Phase
Phase 4
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The objective of the current study is to evaluate the validity of the No Shock, Predictable Shock, Unpredictable Shock (NPU) stressor task for use as a surrogate endpoint to predict short-term clinical outcomes among smokers during a smoking cessation attempt.

Read the detailed description

Smokers recruited for this study are randomly assigned at a screening session to complete the NPU stressor task pre-quit or post-quit (i.e., nicotine deprived or non-deprived). Participants are also randomized to receive either placebo or active combination nicotine replacement therapy (NRT; patches and lozenges) for a two week smoking cessation period. The NPU stressor task measures stressor reactivity to predictable and unpredictable stressors (i.e., electric shock). Startle potentiation during predictable and unpredictable stressors (relative to no-shock) provides the primary measures of stressor reactivity in this task. Predictable and unpredictable startle potentiation are used to calculate overall stressor reactivity and selective unpredictable stressor reactivity. Further detail on these reactivity measures is provided in the Independent Variables section. Detail on the quantification of startle potentiation is provided at the end of this registration.

Smokers provide three weeks (1 week pre-quit, 2 weeks post-quit) of brief 4x daily, real-time web-survey reports of recent cigarette use, NRT use, and other measures not relevant to this study's purpose on the participants' smartphones. At two weeks post-quit, smokers are scheduled for a laboratory visit where participants provide an additional report via staff interview of any smoking during the two-week smoking cessation period.

The stressor reactivity measures from the NPU task will be tested as predictors of clinical outcome (i.e., continuous abstinence during the two-week cessation period) to evaluate the validity of each as surrogate endpoints for use in research on stress mechanisms in smoking relapse. Deprivation status at the time of the NPU stressor task will be examined as a moderator of the effect of stressor reactivity to determine if the surrogate endpoints predict clinical outcome generally or only as deprivation increases.

02

Conditions studied

  • Nicotine Dependence

Browse trials for

03

In context

Tobacco Use Disorder

988 studies on the registry are indexed under Tobacco Use Disorder; 125 are open to participants now.

This study's enrollment of 226 is above the median of 90 across 863 interventional studies indexed under Tobacco Use Disorder.

Browse Tobacco Use Disorder studies →

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,182 studies on the registry; 180 are open to participants now.

Of its 156 completed or terminated interventional studies of FDA-regulated products, 118 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • cigarette use over 10 cigarettes/day for over two years;
  • smoking within the first 30 minutes of waking up
  • expired air carbon monoxide (CO) level >6 ppm
  • self-reported motivation to quit smoking
  • and an agreement to respond to ecological momentary assessment prompts (via SMS) throughout the day for three weeks.

Exclusion criteria

Exclusion Criteria:

  • Health screening are performed by questionnaire and reviewed by study staff (RA or Research Specialist) to ensure that smokers can safely use the nicotine patch and lozenge. Specifically, smokers will be excluded for FDA contraindications for nicotine replacement therapy (i.e., no uncontrolled hypertension, recent myocardial infarction, diabetes, heart disease, asthma, stomach ulcers).
  • All women of child-bearing potential will be required to agree to use an approved method of birth control to prevent pregnancy during the course of the study.
  • All participants will report no medical or psychiatric condition that would contraindicate exposure to electric shock.
  • Participants with uncorrected auditory or visual problems will be excluded.

Additional Data Exclusions

  1. As part of the NPU stressor task, smokers are asked to indicate if the participant "can be shocked in the next 5 seconds" at various points during the task. Responses to these questions are used to verify that the participant understands the cue-shock contingencies. Smokers who answer \< 10 out of 14 questions correctly the NPU stressor task during the experimental session will be excluded from all analyses and replaced.
  2. Smokers with 20% of cue trials identified as artifact in the NPU task will be excluded from all analyses and replaced.
  3. The analysis will NOT exclude smokers who are startle non-responders given that the use of these surrogate endpoints in practice would likely need to include these individuals to avoid unnecessary data loss.
  4. Smokers who do not report a complete abstinence between quit date/time and final laboratory visit (which occurs 12-36 hours later) will be considered to not have quit and will be excluded from all analyses and replaced.
  5. Smokers for whom the investigators cannot definitively quantify an outcome with respect to continuous abstinence will be excluded from all analyses and replaced. Any report of smoking during the two-week cessation period (reported either during the 4x daily web surveys or the laboratory visit at 2 weeks) is sufficient to code the smoker to have lapsed (i.e., not continuously abstinent), even if the participants do not complete the full two weeks of web surveys and/or the 2-week laboratory visit. However, the status of smokers who report no smoking during the cessation attempt but have both a high level of missing data from the web surveys (> 25% of reports) and no two-week laboratory visit report will be deemed uncertain. These smokers will be excluded and replaced.
  6. The investigators will conduct case analyses to identify participants who are model outliers with Bonferroni-corrected studentized residuals p \< 0.05. These model outliers will be excluded but NOT replaced (because the participants are not identified until after data collection has been completed).
05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    Active Deprived

    21 mg nicotine patches and 2 mg nicotine lozenges \+ First NPU task takes place 24 hours after start of quit attempt

    Combination Product: nicotine

  • Experimental
    Active Non-deprived

    21 mg nicotine patches and 2 mg nicotine lozenges \+ First NPU task takes place during normal smoking prior to quit attempt

    Combination Product: nicotine

  • Active comparator
    Placebo Deprived

    Placebo patches and placebo lozenges \+ First NPU task takes place 24 hours after start of quit attempt

    Other: placebo

  • Active comparator
    Placebo Non-deprived

    Placebo patches and placebo lozenges \+ First NPU task takes place during normal smoking prior to quit attempt

    Other: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Stressor Reactivity

    The average of unpredictable startle potentiation and predictable startle potentiation during the first administration of the NPU stressor task.

    Time frame: up to 24 hours after start of cessation attempt (deprived groups); during normal smoking prior to quit attempt, ie. Baseline (non-deprived groups)

  2. Relative Unpredictable Stressor Reactivity

    Unpredictable startle potentiation minus predictable startle potentiation during the first administration of the NPU stressor task

    Time frame: up to 24 hours post cessation attempt (deprived groups); during normal smoking prior to quit attempt, ie. Baseline (non-deprived groups)

  3. Change in Overall Stressor Reactivity

    A difference score of overall stressor reactivity during the second administration of the NPU stressor task relative to the first NPU stressor task

    Time frame: baseline and up to 14 days post cessation attempt (non-deprived groups); baseline and up to 24 hours post quit attempt (deprived groups)

  4. Change in Relative Unpredictable Stressor Reactivity

    A difference score of relative unpredictable stressor reactivity during the second administration of the NPU stressor task relative to the first NPU stressor task

    Time frame: baseline and up to 14 days post cessation attempt (non-deprived groups); baseline and up to 24 hours post quit attempt (deprived groups)

07

Results

Posted Apr 23, 2019

Participant flow

Participant flow — Overall Study
MilestoneActive DeprivedActive Non-DeprivedPlacebo DeprivedPlacebo Non-deprived
Started53535961
Completed35323432
Not completed18212529
Withdrew: Withdrawal by subject1282113
Withdrew: Declined due to shock1223
Withdrew: Protocol violation510213
Withdrew: Data collection artifact0100

Outcome measures

PrimaryOverall Stressor Reactivity

The average of unpredictable startle potentiation and predictable startle potentiation during the first administration of the NPU stressor task.

Time frame:
up to 24 hours after start of cessation attempt (deprived groups); during normal smoking prior to quit attempt, ie. Baseline (non-deprived groups)
Reported as:
Mean · microvolts
Overall Stressor Reactivity
microvoltsActive DeprivedActive Non-deprivedPlacebo DeprivedPlacebo Non-deprived
Overall Stressor Reactivity25.1 ± 23.022.5 ± 24.432.3 ± 29.616.9 ± 17.7
PrimaryRelative Unpredictable Stressor Reactivity

Unpredictable startle potentiation minus predictable startle potentiation during the first administration of the NPU stressor task

Time frame:
up to 24 hours post cessation attempt (deprived groups); during normal smoking prior to quit attempt, ie. Baseline (non-deprived groups)
Reported as:
Mean · microvolts
Relative Unpredictable Stressor Reactivity
microvoltsActive DeprivedActive Non-DeprivedPlacebo DeprivedPlacebo Non-deprived
Relative Unpredictable Stressor Reactivity-6.77 ± 14.0-7.91 ± 14.4-6.06 ± 12.3-4.99 ± 14.0
PrimaryChange in Overall Stressor Reactivity

A difference score of overall stressor reactivity during the second administration of the NPU stressor task relative to the first NPU stressor task

Time frame:
baseline and up to 14 days post cessation attempt (non-deprived groups); baseline and up to 24 hours post quit attempt (deprived groups)
Reported as:
Mean · change in microvolts
Change in Overall Stressor Reactivity
change in microvoltsActive DeprivedActive Non-DeprivedPlacebo DeprivedPlacebo Non-deprived
Change in Overall Stressor Reactivity-2.94 ± 16.30.929 ± 13.0-10.3 ± 24.04.78 ± 13.6
PrimaryChange in Relative Unpredictable Stressor Reactivity

A difference score of relative unpredictable stressor reactivity during the second administration of the NPU stressor task relative to the first NPU stressor task

Time frame:
baseline and up to 14 days post cessation attempt (non-deprived groups); baseline and up to 24 hours post quit attempt (deprived groups)
Reported as:
Mean · change in microvolts
Change in Relative Unpredictable Stressor Reactivity
change in microvoltsActive DeprivedActive Non-DeprivedPlacebo DeprivedPlacebo Non-deprived
Change in Relative Unpredictable Stressor Reactivity1.95 ± 15.53.99 ± 14.80.889 ± 16.0-1.35 ± 11.3

Adverse events

Collected over through 14 days post quit. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Deprived0/35 (0%)0/35 (0%)0/35 (0%)
Active Non-deprived0/32 (0%)0/32 (0%)0/32 (0%)
Placebo Deprived0/34 (0%)0/34 (0%)0/34 (0%)
Placebo Non-deprived0/32 (0%)0/32 (0%)0/32 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Active DeprivedActive Non-DeprivedPlacebo DeprivedPlacebo Non-DeprivedTotal
Mean38.1 ± 10.739.7 ± 12.440.6 ± 12.342 ± 11.340 ± 11.65
Sex: Female, Male
Sex: Female, Male(Participants)Active DeprivedActive Non-DeprivedPlacebo DeprivedPlacebo Non-DeprivedTotal
Female1413121150
Male2119222183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active DeprivedActive Non-DeprivedPlacebo DeprivedPlacebo Non-DeprivedTotal
Hispanic or Latino10102
Not Hispanic or Latino34323332131
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active DeprivedActive Non-DeprivedPlacebo DeprivedPlacebo Non-DeprivedTotal
American Indian or Alaska Native01113
Asian001001
Native Hawaiian or Other Pacific Islander00000
Black or African American9711936
White2621212189
More than one race02114
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Active DeprivedActive Non-DeprivedPlacebo DeprivedPlacebo Non-DeprivedTotal
United States35323432133
08

Study locations

1 site
  • University of Wisconsin
    Madison, Wisconsin 53706, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · May 30, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — IPD will be shared on the data repository at Open Science Foundation

Supporting information: Study protocol, Analytic code

Time frame: Data will be available on submission of first manuscript based on study

Access criteria: Data are completely open

Data sharing details ↗ · osf.io

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03262233
Responsible party
Sponsor
First posted
Aug 25, 2017
Start date
Apr 1, 2015
Primary completion
Feb 20, 2018
Completion
Feb 20, 2018
Results posted
Apr 23, 2019
Last update
Apr 23, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicotine

Start the discussion